ASCO: Pomalidomide New Standard of Care in Heavily Pretreated, Relapsed Multiple Myeloma

Pomalidomide in combination with low-dose dexamethasone had a highly significant benefit on progression-free survival and overall survival compared with single-agent high-dose dexamethasone in patients with relapsed or refractory multiple myeloma, according to updated results of the MM-03 trial presented at the ASCO 2013 Annual Meeting.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news